zdorПроблемы здоровья и экологииHealth and Ecology Issues2220-09672708-6011Gomel State Medical University10.51523/2708-6011.2019-16-1-4zdor-90Research ArticleКЛИНИЧЕСКАЯ МЕДИЦИНАCLINICAL MEDICINEПЛЕЙОТРОПНЫЕ ЭФФЕКТЫ АТОРВАСТАТИНА У ПАЦИЕНТОВ С ХРОНИЧЕСКОЙ ОБСТРУКТИВНОЙ БОЛЕЗНЬЮ ЛЕГКИХ: ВЛИЯНИЕ НА ПОКАЗАТЕЛИ ОКСИДАТИВНОГО СТРЕССАThe Pleoitropic Effects of Atorvastatin in Patients with Chronic Obstructive Pulmonary Disease: the Influence on the Indicators of Oxidative StressШолковаМ. В.SholkovaM. V.noemail@neicon.ruДоценкоЭ. А.DotsenkoE. A.noemail@neicon.ruБураковИ. И.BurakovI. I.noemail@neicon.ruГончарикА. В.GoncharikA. V.noemail@neicon.ruИбрагимоваЖ. А.IbragimovaZh. A.noemail@neicon.ruУчреждение образования «Белорусский государственный медицинский университет»Belarus201928032019012024Copyright © Шолкова М.В., Доценко Э.А., Бураков И.И., Гончарик А.В., Ибрагимова Ж.А., 20192019Шолкова М.В., Доценко Э.А., Бураков И.И., Гончарик А.В., Ибрагимова Ж.А.Sholkova M.V., Dotsenko E.A., Burakov I.I., Goncharik A.V., Ibragimova Z.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.gsmu.by/jour/article/view/90

Цель: изучить динамику маркеров оксидативного стресса у пациентов с хронической обструктивной болезнью легких (ХОБЛ) при приеме аторвастатина. Материал и методы. В исследование было включено 52 пациента с ХОБЛ в сочетании с гиперлипидемией. Основная группа (n = 30) в дополнение к стандартной терапии получала аторвастатин в дозе 20 мг в сутки. Группа сравнения (n = 22) получала только стандартное лечение ХОБЛ. Наблюдение за пациентами велось на протяжении 24 недель. Для оценки оксидативного стресса оценивали уровень малонового диальдегида, супероксиддисмутазы и каталазы. Результаты. В группе пациентов, принимавших аторвастатин, уровень супероксиддисмутазы снизился с 949 [608; 1042] ед/мл исходно до 406 [319; 478] ед/мл через 24 недели (р = 0,035). Уровень каталазы и малонового диальдегида существенно не изменился как в опытной группе, так и в группе сравнения. Заключение. При приеме аторвастатина уровень супероксиддисмутазы снижается, что может указывать на уменьшение уровня оксидативного стресса у пациентов с ХОБЛ.

Objective: to evaluate the dynamics of the markers of oxidative stress in patients with chronic obstructive pulmonary disease (COPD) during the application of atorvastatin. Material and methods. The study included 52 COPD patients with concomitant hyperlipidemia. The main group (n = 30) were given atorvastatin at a dosage of 20 mg per day in addition to the standard COPD treatment. The comparison group (n = 22) only underwent the standard COPD treatment. The patients were monitored for 24 weeks. The levels of superoxide dismutase, catalase and malondialdehyde were evaluated for the assessment of oxidative stress. Results. In the group of the patients taking atorvastatin, the level of superoxide dismutase decreased from 949 [608; 1042] units/ml initially to 406 [319; 478] u/ml after 24 weeks (p = 0.035). The levels of catalase and malondialdehyde did not change significantly both in the experimental and comparison groups. Conclusion. The intake of atorvastatin decreases the level of superoxide dismutase, which may indicate a decrease in the level of oxidative stress in COPD patients.

аторвастатиндислипидемияхроническая обструктивная болезнь легкихоксидативный стрессatorvastatinhyperlipidemiachronic obstructive pulmonary diseaseoxidative stressReferencesGOLD, the Global Initiative for Chronic Obstructive Lung Disease. [Electronic resource]. [cited 2015 April 12]. Available from: http://goldcopd.org/.GOLD, the Global Initiative for Chronic Obstructive Lung Disease. [Electronic resource]. [cited 2015 April 12]. Available from: http://goldcopd.org/.Pavord ID, Beasley R, Agusti A, Anderson GP, Bel E, Brusselle G, Cullinan P, Custovic A, Ducharme FM, Fahy JV, Frey U, Gibson P, Heaney LG, Holt PG, Humbert M, Lloyd CM, Marks G, Martinez FD, Sly PD, von Mutius E, Wenzel S, Zar HJ, Bush A. After asthma: redefining airways diseases. Lancet. 2018 Jan 27;391(10118):350-400. doi: 10.1016/S0140-6736(17)30879-6.Pavord ID, Beasley R, Agusti A, Anderson GP, Bel E, Brusselle G, Cullinan P, Custovic A, Ducharme FM, Fahy JV, Frey U, Gibson P, Heaney LG, Holt PG, Humbert M, Lloyd CM, Marks G, Martinez FD, Sly PD, von Mutius E, Wenzel S, Zar HJ, Bush A. After asthma: redefining airways diseases. Lancet. 2018 Jan 27;391(10118):350-400. doi: 10.1016/S0140-6736(17)30879-6.Fischer BM, Voynow JA, Ghio AJ. COPD: balancing oxidants and antioxidants. Int J Chron Obstruct Pulmon Dis. 2015 Feb 2;10:261-76. doi: 10.2147/COPD.S10770Fischer BM, Voynow JA, Ghio AJ. COPD: balancing oxidants and antioxidants. Int J Chron Obstruct Pulmon Dis. 2015 Feb 2;10:261-76. doi: 10.2147/COPD.S10770Ahmad A, Shameem M, Husain Q. Altered oxidant-antioxidant levels in the disease prognosis of chronic obstructive pulmonary disease. Int J Tuberc Lung Dis. 2013 Aug;17(8):1104-9. doi: 10.5588/ijtld.12.0512.Ahmad A, Shameem M, Husain Q. Altered oxidant-antioxidant levels in the disease prognosis of chronic obstructive pulmonary disease. Int J Tuberc Lung Dis. 2013 Aug;17(8):1104-9. doi: 10.5588/ijtld.12.0512.Zuo L, He F, Sergakis GG, Koozehchian MS, Stimpfl JN, Rong Y, Diaz PT, Best TM. Interrelated role of cigarette smoking, oxidative stress, and immune response in COPD and corresponding treatments. Am J Physiol Lung Cell Mol Physiol. 2014 Aug 1;307(3):L205-18. doi:10.1152/ajplung.00330.2013.Zuo L, He F, Sergakis GG, Koozehchian MS, Stimpfl JN, Rong Y, Diaz PT, Best TM. Interrelated role of cigarette smoking, oxidative stress, and immune response in COPD and corresponding treatments. Am J Physiol Lung Cell Mol Physiol. 2014 Aug 1;307(3):L205-18. doi:10.1152/ajplung.00330.2013.Kirkham PA, Barnes PJ. Oxidative stress in COPD. Chest. 2013 Jul;144(1):266-273. doi: 10.1378/chest.12-2664.Kirkham PA, Barnes PJ. Oxidative stress in COPD. Chest. 2013 Jul;144(1):266-273. doi: 10.1378/chest.12-2664.Rothnie KJ, Yan R, Smeeth L, Quint JK. Risk of myocardial infarction (MI) and death following MI in people with chronic obstructive pulmonary disease (COPD): a systematic review and meta-analysis. BMJ Open. 2015. 2015 Sep 11;5(9):e007824. doi: 10.1136/bmjopen-2015-007824. [Electronic resource]. [cited 2018 March 11]. Available from: https://www.ncbi.nlm.nih.gov/ pubmed/26362660.Rothnie KJ, Yan R, Smeeth L, Quint JK. Risk of myocardial infarction (MI) and death following MI in people with chronic obstructive pulmonary disease (COPD): a systematic review and meta-analysis. BMJ Open. 2015. 2015 Sep 11;5(9):e007824. doi: 10.1136/bmjopen-2015-007824. [Electronic resource]. [cited 2018 March 11]. Available from: https://www.ncbi.nlm.nih.gov/ pubmed/26362660.Yorulmaz H, Ozkok E, Kaptan E, Ates G, Tamer S. Therapeutic effects of simvastatin on Galectin-3 and oxidative stress parameters in endotoxemic lung tissue. Biosci Rep. 2018 Jun 27;38(3). pii: BSR20180308. doi: 10.1042/BSR20180308. [Electronic resource]. [cited 2019 January 17]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6019383/Yorulmaz H, Ozkok E, Kaptan E, Ates G, Tamer S. Therapeutic effects of simvastatin on Galectin-3 and oxidative stress parameters in endotoxemic lung tissue. Biosci Rep. 2018 Jun 27;38(3). pii: BSR20180308. doi: 10.1042/BSR20180308. [Electronic resource]. [cited 2019 January 17]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6019383/Margaritis M, Channon KM, Antoniades C. Statins as regulators of redox state in the vascular endothelium: beyond lipid lowering. Antioxid Redox Signal. 2014 Mar 10;20(8):1198-215. doi: 10.1089/ars.2013.5430.Margaritis M, Channon KM, Antoniades C. Statins as regulators of redox state in the vascular endothelium: beyond lipid lowering. Antioxid Redox Signal. 2014 Mar 10;20(8):1198-215. doi: 10.1089/ars.2013.5430.Attalla DM, Ahmed LA, Zaki HF, Khattab MM. Paradoxical effects of atorvastatin in isoproterenol-induced cardiotoxicity in rats: Role of oxidative stress and inflammation. Biomed Pharmacother. 2018 Aug;104:542-49. doi:10.1016/j.biopha.2018.05.005.Attalla DM, Ahmed LA, Zaki HF, Khattab MM. Paradoxical effects of atorvastatin in isoproterenol-induced cardiotoxicity in rats: Role of oxidative stress and inflammation. Biomed Pharmacother. 2018 Aug;104:542-49. doi:10.1016/j.biopha.2018.05.005.Ahmadi Y, Ghorbanihaghjo A, Naghi-Zadeh M, Yagin NL. Oxidative stress as a possible mechanism of statin-induced myopathy. Inflammopharmacology. 2018 Jun;26(3):667-674. doi: 10.1007/s10787-018-0469-xAhmadi Y, Ghorbanihaghjo A, Naghi-Zadeh M, Yagin NL. Oxidative stress as a possible mechanism of statin-induced myopathy. Inflammopharmacology. 2018 Jun;26(3):667-674. doi: 10.1007/s10787-018-0469-xAsakawa T, Matsushita S. Coloring Condition of Thiobarbituric Acid Test for Detecting Lipid Hydroperoxides. Lipids Lipids. 1979;15(3):137-140.Asakawa T, Matsushita S. Coloring Condition of Thiobarbituric Acid Test for Detecting Lipid Hydroperoxides. Lipids Lipids. 1979;15(3):137-140.Ramkumar S., Raghunath A., Raghunath S.Statin Therapy: Review of Safety and Potential Side Effects. Acta Cardiol Sin. 2016;32(6):631-39. doi: 10.6515/ACS20160611A.Ramkumar S., Raghunath A., Raghunath S.Statin Therapy: Review of Safety and Potential Side Effects. Acta Cardiol Sin. 2016;32(6):631-39. doi: 10.6515/ACS20160611A.Saku K, Zhang B, Noda K; PATROL Trial Investigators. Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): the PATROL trial. Circ J. 2011;75(6):1493-505. doi:10.1253/circj.CJ-10-1281.Saku K, Zhang B, Noda K; PATROL Trial Investigators. Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): the PATROL trial. Circ J. 2011;75(6):1493-505. doi:10.1253/circj.CJ-10-1281.Pytel E, Jackowska P, Chwatko G, Olszewska-Banaszczyk M, Koter-Michalak M, Kubalczyk P, Broncel M. Intensive statin therapy, used alone or in combination with ezetimibe, improves homocysteine level and lipid peroxidation to a similar degree in patients with coronary artery diseases. Pharmacol Rep. 2016 Apr;68(2):344-8. doi: 10.1016/j.pharep.2015.08.019.Pytel E, Jackowska P, Chwatko G, Olszewska-Banaszczyk M, Koter-Michalak M, Kubalczyk P, Broncel M. Intensive statin therapy, used alone or in combination with ezetimibe, improves homocysteine level and lipid peroxidation to a similar degree in patients with coronary artery diseases. Pharmacol Rep. 2016 Apr;68(2):344-8. doi: 10.1016/j.pharep.2015.08.019.Nikolic T, Zivkovic V, Srejovic I, Stojic I, Jeremic N, Jeremic J, Radonjic K, Stankovic S, Obrenovic R, Djuric D, Jakovljevic V. Effects of atorvastatin and simvastatin on oxidative stress in diet-induced hyperhomocysteinemia in Wistar albino rats: a comparative study. Mol Cell Biochem. 2018 Jan;437(1-2):109-18. doi: 10.1007/s11010-017-3099-5.Nikolic T, Zivkovic V, Srejovic I, Stojic I, Jeremic N, Jeremic J, Radonjic K, Stankovic S, Obrenovic R, Djuric D, Jakovljevic V. Effects of atorvastatin and simvastatin on oxidative stress in diet-induced hyperhomocysteinemia in Wistar albino rats: a comparative study. Mol Cell Biochem. 2018 Jan;437(1-2):109-18. doi: 10.1007/s11010-017-3099-5.Ferreira TS, Lanzetti M, Barroso MV, Rueff-Barroso CR, Benjamim CF, de Brito-Gitirana L, Porto LC, Valença SS. Oxidative stress and inflammation are differentially affected by atorvastatin, pravastatin, rosuvastatin, and simvastatin on lungs from mice exposed to cigarette smoke. Inflammation. 2014 Oct;37(5):1355-65. doi: 10.1007/s10753-014-9860-y.Ferreira TS, Lanzetti M, Barroso MV, Rueff-Barroso CR, Benjamim CF, de Brito-Gitirana L, Porto LC, Valença SS. Oxidative stress and inflammation are differentially affected by atorvastatin, pravastatin, rosuvastatin, and simvastatin on lungs from mice exposed to cigarette smoke. Inflammation. 2014 Oct;37(5):1355-65. doi: 10.1007/s10753-014-9860-y.Melo AC, Valença SS, Gitirana LB, Santos JC, Ribeiro ML, Machado MN, Magalhães CB, Zin WA, Porto LC. Redox markers and inflammation are differentially affected by atorvastatin, pravastatin or simvastatin administered before endotoxin-induced acute lung injury. Int Immunopharmacol. 2013 Sep;17(1):57-64. doi.org/10.1016/j.intimp.2013.05.016.Melo AC, Valença SS, Gitirana LB, Santos JC, Ribeiro ML, Machado MN, Magalhães CB, Zin WA, Porto LC. Redox markers and inflammation are differentially affected by atorvastatin, pravastatin or simvastatin administered before endotoxin-induced acute lung injury. Int Immunopharmacol. 2013 Sep;17(1):57-64. doi.org/10.1016/j.intimp.2013.05.016.

The authors declare that there are no conflicts of interest present.